Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

this study were presented today at the 2011 Annual Meeting of ASCO and the full ASCO presentation is posted on our website.

Two ongoing studies, initiated in Q1 2011, are evaluating PCI-32765 in combination with standard therapies for CLL/SLL. We have enrolled 34 patients in these studies and anticipate completing enrollment in 2011.

From these studies, we expect to be able to analyze initial 3-month safety data for ofatumumab/PCI-32765 and bendamustine/rituximab/PCI-32765 in the second half of 2011. To date the preliminary safety data from these combination studies suggests that these combinations are likely to be safe.

Based on the significant single-agent activity in CLL/SLL from the ongoing Phase IB/II trial, and contingent upon confirmation of 3-month combination safety data, Phase III planning is currently underway. We expect to initiate a Phase III study in CLL/ SLL in the first half of 2012.  

-- Mantle Cell Lymphoma (MCL)
A Phase II study of single-agent PCI-32765 in relapsed or refractory MCL (PCYC-1104) began enrolling patients in late February 2011. To date, we have enrolled 30 patients on this trial and anticipate completing enrollment by the end of calendar 2011. Initial review of early data from this ongoing study suggests that the high overall response rate observed in Phase I is likely to be similar in Phase II. We anticipate submitting an abstract with interim results for presentation at the 2011 American Society of Hematology (ASH) Meeting. Contingent upon the ongoing analysis of PCYC-1104, we will soon begin Phase III planning in MCL. We anticipate that a Phase III study will be initiated in 2012.

-- Diffuse Large B-Cell Lymphoma (DLBCL)
A multicenter, open-label, Phase II study of PCI-32765 in patients with relapsed or refractory DLBCL (PCYC-1106) began enrollment in May 2011. This study is designed to assess the activity of PCI-32765 in two genetically distinct subt
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  According to their CEO, Rob Bohacs ... is going through a complete transformation with highly ... the current clinical trial management process isn,t configured ... trials, which will ultimately drive the prescription cancer ... has been recognized by the National Cancer Institute as ...
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... -- A study using a relatively new imaging tool, ... the composition of carotid artery disease and has the ... disease, a leading cause of stroke. ... 2010 and May 2012, was featured in the June ... College of Cardiology (JACC) Cardiovascular Interventions. Interventional cardiologist ...
Breaking Medicine Technology:Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... 21, 2012 InterMune, Inc. (NASDAQ: ITMN ... agreement with Vidara Therapeutics International Limited (Vidara) to sell ... transaction valued at $55 million plus a two-year royalty ... group of companies with operations in Ireland and the ...
... 2012  Consumers Union, the policy and advocacy arm of Consumer Reports, ... patients at risk in a full-page print ad in ... vote on a bill this week to reauthorize the statute governing ... that the FDA does not have the power under current law ...
Cached Medicine Technology:InterMune to Divest Actimmune® (Interferon Gamma-1b) 2InterMune to Divest Actimmune® (Interferon Gamma-1b) 3Dangerous Medical Device Loophole Puts Patients At Risk 2Dangerous Medical Device Loophole Puts Patients At Risk 3
(Date:10/1/2014)... D.C. and ATLANTA (PRWEB) October 01, 2014 ... information security executive networking and relationship-marketing firm, ... 2014 Information Security Executive® and Project of ... include top-ranking decision makers representing organizations in ... academics. Projects include large-scale technology endeavors that ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Beverly Hills ... Kathleen Mojas is celebrating 20 years of private practice ... hundreds of people to achieve greater joy and fulfillment ... list of warning signs and suggestions for anyone who ... Mojas explains: “Believe it or not, it’s not ...
(Date:10/1/2014)... Inc., announced today their new NoteSwift™ 2.0 for Allscripts ... the bridge between the EHR and Dragon Medical interpreting ... at the point of care. NoteSwift reduces the time ... than half – and virtually eliminates mouse clicks – ... EHR use according to the June 12, 2014 HIMSS ...
(Date:10/1/2014)... the occasion of the Leishmaniasis East Africa Platform ... international leishmaniasis experts, results of a pharmacovigilance ... plan, carried out by MSF, DNDi, and national ... presented to key decision makers in order to ... the combination of Sodium Stibogluconate and Paromomycin (SSG&PM) ...
(Date:10/1/2014)... 01, 2014 Dr. Saj Jivraj, one ... prosthodontists, is traveling to Chennai, India, tomorrow to speak ... 2 and 3. , Dr. Jivraj is founder of ... Oxnard, Calif., and one of the world’s foremost prosthodontists, ... replacement. He is speaking to the Indian Society of ...
Breaking Medicine News(10 mins):Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... scientists assumed that the adult heart is unable to ... Center for Molecular Medicine (MDC) Berlin-Buch and the Charit ... that this dogma no longer holds true. Dr. Laura ... able to show that the body`s own heart muscle ...
... Free Bench-Top Flow Cytometer System Twice Yearly to Support Innovative ... , -Learn More about the Revolutionary ... Biology Annual Meeting- , , ... life sciences company developing revolutionary bench-top flow cytometer systems, today ...
... LLP today announced,that, effective January 1, 2009, it ... and regulation practice. MARC Associates are experts in ... distinguished client base.,Other areas of expertise include energy ... "We have been ...
... age of 100 and never looking a day over 60 is now ... now, this information is available to everyone absolutely free. , ... ... Health News Report is offering a free download to the popular book ...
... hemodynamic monitor (IHM) may help to guide medical treatment ... with diastolic heart failure (DHF), reports a study in ... http://www.onlinejcf.com/ ), published by Elsevier. , Led by Michael ... Charleston, the researchers analyzed data on DHF patients enrolled ...
... Dec. 11 Perot Systems Corporation,(NYSE: ... the Daughters,of Charity Health System (DCHS) has awarded ... Under terms of the agreement, Perot Systems will ... application implementation and,support, desktop support, local and wide ...
Cached Medicine News:Health News:Heart regenerates after infarction -- first trials with mice 2Health News:Researcher Receives Free Flow Cytometer System as First Winner of Accuri(R) Flow Cytometer Creativity Awards Program 2Health News:Researcher Receives Free Flow Cytometer System as First Winner of Accuri(R) Flow Cytometer Creativity Awards Program 3Health News:Researcher Receives Free Flow Cytometer System as First Winner of Accuri(R) Flow Cytometer Creativity Awards Program 4Health News:Holland & Knight Welcomes MARC Associates - Experts in Health Care and Intergovernmental Policy - to the Firm's Public Policy & Regulation Practice 2Health News:Holland & Knight Welcomes MARC Associates - Experts in Health Care and Intergovernmental Policy - to the Firm's Public Policy & Regulation Practice 3Health News:Holland & Knight Welcomes MARC Associates - Experts in Health Care and Intergovernmental Policy - to the Firm's Public Policy & Regulation Practice 4Health News: Anti-Aging Miracle Physicians Have Been Waiting for is Finally Here : Free Book Available From Natural Health News Report Reveals the Secret to Staying Young 2Health News:Implantable monitor may help in managing diastolic heart failure 2Health News:Perot Systems Awarded Contract Extension By Daughters of Charity 2Health News:Perot Systems Awarded Contract Extension By Daughters of Charity 3
This standard tying forcep is curved with 5mm titanium coated platforms. Length 85 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson tying forceps with serrated handle, platform 4 mm and overall length of 85 mm....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Medicine Products: